Median Technologies Announces a 40 Million Euro Capital Increase

Use of Proceeds and Cash Flow Timeline

The net proceeds from the capital increase will be allocated to accelerate the commercialization of Eyonis LCS in the US and its launch in targeted European countries, as well as to the development of new indications in oncology. The operation is expected to extend the company's cash flow horizon until the first half of 2028 if subscribed at 100%. Median Technologies notes that 12 million share warrants issued in July 2025 remain outstanding, with a maturity date in January 2028, and an exercise price of 2.39 euros per share. If these warrants are fully exercised, this horizon could be extended to mid-2029.

Structure of the Offer and Shareholder Commitments

The capital increase includes a public offering in France and a global placement to qualified investors for 40 million euros, as well as an offer reserved for guarantors up to a maximum of 10 million euros. The subscription price is set at 5 euros per ordinary share, representing a discount of 2.85% compared to the weighted average of the prices of the twenty sessions preceding May 26, 2026. Lion Point Capital commits to subscribe and guarantee up to 30 million euros under a backstop agreement. The guarantors (Katarina Martinson AB, Venture Sarl, and Nordica Life (Bermuda) Ltd) will receive a commission of 8% of the total amount of their commitments, equivalent to 2.4 million euros, payable in new shares. The subscription period for the public offering runs from May 27 to June 3, 2026, at 5 PM (Paris time). The settlement-delivery and the admission of the new shares on Euronext Growth are scheduled for June 9, 2026.